Udvalget var derudover betænkeligt ved, at virksomheden ikke havde påvist, at den ville have været i stand til at overvåge kvaliteten af lægemidlet og holde den på et acceptabelt niveau.
In addition, the Committee was concerned that the company had not demonstrated that it would have been able to monitor the quality of the medicine to an acceptable level.